Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELIXOPHYLLIN SR vs AMINOPHYLLINE DYE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and antagonizing adenosine receptors. It also has anti-inflammatory effects by reducing eosinophil infiltration and cytokine release.
Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular c AMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Off-label: Treatment of apnea of prematurity, bradycardia in preterm infants, and respiratory depression due to opioid overdose
Treatment of bronchospasm associated with asthma, chronic bronchitis, emphysema, and COPD,Apnea of prematurity (off-label)
300-600 mg orally every 12 hours; extended-release tablets. Adjust based on serum theophylline concentrations (target 5-15 mcg/m L).
Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).
Terminal elimination half-life: 7-9 hours in adults (nonsmokers). In smokers, hepatic clearance is increased, reducing half-life to 4-5 hours. In patients with hepatic cirrhosis, half-life may extend to 24 hours. In neonates, half-life is prolonged (20-30 hours).
Terminal elimination half-life is approximately 7-9 hours in healthy adults. In smokers, half-life decreases to 4-5 hours. In patients with hepatic cirrhosis, heart failure, or COPD, half-life may prolong to 20-30 hours.
Hepatic via cytochrome P450 isoenzymes, primarily CYP1A2, with minor contributions from CYP2E1 and CYP3A4.
Primarily hepatic via CYP1A2, with minor contributions from CYP3A4, CYP2E1, and CYP2D6. Metabolism may be saturated, leading to nonlinear kinetics at therapeutic doses.
Renal: approximately 90% of the dose is eliminated via hepatic metabolism (N-demethylation and hydroxylation), with about 10% excreted unchanged in urine. The primary metabolites are 1-methylxanthine, 1,3-dimethyluric acid, and 3-methylxanthine. Fecal excretion is negligible (<1%).
Primarily hepatic metabolism (approximately 90%) to 1,3-dimethyluric acid and other metabolites; renal excretion of unchanged drug accounts for about 10-13% of the dose. Less than 1% is excreted via bile or feces.
Approximately 40% bound to albumin. Binding is reversible and concentration-independent.
Approximately 40% bound, primarily to albumin. In neonates, protein binding is lower (about 30%).
Apparent Vd: 0.3-0.7 L/kg. This reflects distribution throughout total body water, with slightly higher distribution in neonates (0.8-1.0 L/kg) due to lower protein binding. The Vd is relatively small, indicating limited tissue binding.
Approximately 0.5 L/kg (range 0.3-0.7 L/kg). Higher in premature infants and neonates (0.6-0.9 L/kg). Vd corresponds to total body water; aminophylline distributes into extracellular and intracellular fluid.
Oral (sustained-release): 96-100% relative to oral immediate-release formulations. The sustained-release formulation yields lower peak concentrations but similar AUC. Food may increase peak concentration slightly (by about 10%) but does not affect overall bioavailability.
Oral immediate-release: nearly 100%. Oral sustained-release: 80-100% depending on formulation. Rectal: variable (80-100%). Intravenous: 100%.
No specific GFR-based dose reduction required; monitor serum levels closely. Theophylline clearance may be decreased in patients with impaired renal function, necessitating dose individualization.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min: reduce dose by 50% and monitor serum theophylline levels closely.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 50-75%; Child-Pugh C: reduce dose by 75% or avoid use. These recommendations are based on decreased clearance; monitor serum levels.
Child-Pugh Class A: reduce dose by 50%. Child-Pugh Class B: reduce dose by 75%. Child-Pugh Class C: use alternative therapy or reduce dose by 80-90% with close monitoring.
Initial dose: 10-14 mg/kg/day orally divided every 12 hours; may increase gradually based on serum concentrations. Maximum: 16 mg/kg/day for children 1-9 years; 12 mg/kg/day for children 9-16 years. Use extended-release tablets only in children who can swallow tablets whole.
Loading dose: 5-6 mg/kg IV over 30 minutes. Maintenance IV infusion: age 1-6 months: 0.5 mg/kg/hour; 6-12 months: 0.6-0.7 mg/kg/hour; 1-9 years: 0.8-1.0 mg/kg/hour; >9 years: 0.5-0.7 mg/kg/hour. Oral: 5-6 mg/kg every 6 hours (immediate-release) or every 12 hours (extended-release).
Lower initial doses recommended (e.g., 300 mg/day) due to reduced clearance; monitor serum theophylline concentrations closely. Avoid in patients with significant cardiac or hepatic impairment.
Lower initial doses recommended (e.g., 300-400 mg/day oral) with slower titration, as clearance is decreased. Monitor serum theophylline levels and adjust to achieve 5-15 mcg/m L.
None.
Theophylline has a narrow therapeutic index; serum levels must be monitored. Severe toxicity can occur at levels above 20 mcg/m L, including seizures, cardiac arrhythmias, and death. Use with caution as serious adverse effects may occur without warning.
Consider dose adjustment in patients with hepatic impairment, cardiac dysfunction, or those on drugs that alter theophylline metabolism (e.g., cimetidine, fluoroquinolones, macrolides).,Monitor serum theophylline levels to avoid toxicity (therapeutic range: 10-20 mcg/m L).,Seizure, cardiac arrhythmias, and death can occur at high serum concentrations.,Use with caution in patients with peptic ulcer disease, seizures, or hypothyroidism.,Elderly patients and those with underlying cardiac disease are at increased risk of adverse effects.
Monitor serum theophylline levels; adjust dose accordingly,Risk of toxicity is increased in patients with hepatic impairment, congestive heart failure, cor pulmonale, and elderly patients,May exacerbate or induce peptic ulcer disease, seizures, and other cardiac arrhythmias,Concurrent use with other xanthines can increase toxicity,Smoking cessation decreases clearance and may require dose reduction
Hypersensitivity to theophylline or any component of the formulation,Use of fixed-dose combination products with ephedrine (due to increased risk of CNS stimulation and cardiac effects)
Hypersensitivity to theophylline or any component,Active seizure disorder unless adequately controlled with medications,Severe cardiac arrhythmias (e.g., ventricular tachycardia),Pregnancy (controversial; use only if clearly needed)
Avoid large amounts of caffeine (coffee, tea, chocolate). Charcoal-grilled foods may decrease absorption. High-protein, low-carbohydrate diets may alter metabolism.
Avoid excessive intake of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may potentiate stimulant effects and increase risk of toxicity. High-fat meals may slow absorption of extended-release formulations. No other significant food interactions.
Theophylline crosses the placenta. First trimester: Limited data, but no major teratogenic effects reported in human studies; animal studies show no evidence of teratogenicity. Second and third trimesters: No known teratogenic risk; fetal serum levels approximate maternal levels. Use only if clearly needed.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Potential risk of fetal tachycardia, jitteriness, and hypoglycemia due to maternal theophylline levels; no clear teratogenic signal. Close monitoring recommended.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.7. At maternal therapeutic doses, infant exposure is low (estimated 1-10% of maternal weight-adjusted dose), and adverse effects are rare. However, some infants may experience irritability or insomnia. Caution is advised in premature infants or those with impaired clearance.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant serum levels are typically subtherapeutic, but irritability, jitteriness, and feeding intolerance have been reported. Caution advised; monitor infant for adverse effects. Benefit-risk assessment required.
During pregnancy, theophylline clearance may decrease in the third trimester due to reduced hepatic metabolism, leading to increased serum concentrations. Dose adjustments may be necessary, guided by serum level monitoring. Postpartum, clearance returns to non-pregnant levels within 2-4 weeks, requiring further dose adjustment.
Pregnancy increases theophylline clearance by 20-40% due to increased hepatic metabolism and renal blood flow. Monitor serum levels and adjust dose to maintain therapeutic range. Consider extended-release formulations for stable levels. Postpartum: clearance may decrease rapidly, requiring dose reduction.
Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L). Sustained-release formulation allows twice-daily dosing. Use with caution in patients with hepatic impairment, heart failure, or fever, as clearance is reduced. Caffeine may increase toxicity.
Aminophylline is a bronchodilator that contains theophylline and ethylenediamine. Use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L). Avoid use in patients with active peptic ulcer disease. Ethylenediamine component may cause allergic reactions in sensitive patients. Dose adjustment required in hepatic impairment, heart failure, or elderly. Tachyphylaxis may occur with prolonged use. Cigarette smoking increases clearance; monitor levels closely. Consider drug interactions with cimetidine, fluoroquinolones, and macrolides which decrease clearance.
Swallow tablet whole; do not crush or chew.,Take doses 12 hours apart consistently with or without food.,Avoid caffeine-containing beverages and foods.,Report symptoms of toxicity: nausea, vomiting, insomnia, palpitations.,Do not change brand without consulting prescriber.
Do not chew or crush extended-release tablets; swallow whole.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity such as nausea, vomiting, insomnia, rapid heartbeat, or seizures immediately.,Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Inform your doctor if you have a history of seizures, ulcers, or liver disease.,Do not smoke or stop smoking without medical advice as it affects how this medication works.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELIXOPHYLLIN SR vs AMINOPHYLLINE DYE FREE, answered by our medical review team.
ELIXOPHYLLIN SR is a Xanthine Bronchodilator that works by Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and antagonizing adenosine receptors. It also has anti-inflammatory effects by reducing eosinophil infiltration and cytokine release.. AMINOPHYLLINE DYE FREE is a Xanthine Bronchodilator that works by Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular c AMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELIXOPHYLLIN SR and AMINOPHYLLINE DYE FREE depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELIXOPHYLLIN SR is: 300-600 mg orally every 12 hours; extended-release tablets. Adjust based on serum theophylline concentrations (target 5-15 mcg/m L).. The standard adult dose of AMINOPHYLLINE DYE FREE is: Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELIXOPHYLLIN SR and AMINOPHYLLINE DYE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELIXOPHYLLIN SR is classified as Category C. Theophylline crosses the placenta. First trimester: Limited data, but no major teratogenic effects reported in human studies; animal studies show no evidence of teratogenicity. Sec. AMINOPHYLLINE DYE FREE is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Potential risk of. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.